A recently-approved test now allows doctors to measure exactly how much hepatitis B surface antigen (HBsAg) people with chronic hepatitis B have in their blood;

The National Research Council (NRC) in Canada has awarded ContraVir Pharmaceuticals more than $224,000 to cover expenses related to the preclinical development of CRV431, the company’s cyclophilin inhibitor for the treatment of hepatitis B virus (HBV).

Antioxidants are believed to prevent some chronic illnesses - such as cardiovascular disease and cancer - due to their ability to protect against cell damage.

Researchers in Spain have discovered that a protein called CPEB4 may help to prevent fatty liver, a condition in which fat builds up in the liver.

Quest Diagnostics launched a new quantitative test that will help doctors in the U.S. measure a patient’s response to therapy while being treated for hepatitis B virus (HBV) infection.

The hepatitis C drug Sovaldi (sofosbuvir) can adversely interact with the human immunodeficiency virus (HIV) drug Viread (tenofovir disoproxil), according to recent findings. Both drugs are manufactured and commercialized by Gilead Sciences.

Chronic Hepatitis C (CHC) has been undertreated among elderly patients. Interferon-free treatment represents an opportunity for these patients. The aim of the study was to assess the cost-effectiveness of Directly Acting Antivirals (DAAs) in CHC elderly patients.

Treatments combining Benitec Biopharma’s investigative agents — BB-101, BB-102 or BB-103 — with current standard of care may be a way of treating hepatitis B virus (HBV) infection, according to results obtained in an animal study.

Diet-related diseases like non-alcoholic fatty liver disease (NAFLD) are known to have a major inflammatory component. However, the molecular pathways linking diet-induced changes with inflammation remained elusive.

With the holidays come family reunions and parties that can set the stage for some big emotional challenges for people living with hepatitis B.